S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:DICE

DICE Therapeutics (DICE) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$47.55
$47.55
50-Day Range
$46.62
$47.55
52-Week Range
$15.08
$47.90
Volume
N/A
Average Volume
1.03 million shs
Market Capitalization
$2.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.75
DICE stock logo

About DICE Therapeutics Stock (NASDAQ:DICE)

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.

DICE Stock News Headlines

[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Can a Big Pharma Ever Be Worth $1 Trillion?
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Q3 2023 Eli Lilly and Co Earnings Call
Eli Lilly to buy Dice Therapeutics for $2.4 billion
Wells Fargo Sticks to Their Hold Rating for Incyte (INCY)
What 9 Analyst Ratings Have To Say About DICE Therapeutics
Lilly Completes Acquisition of DICE Therapeutics
Lilly Extends Tender Offer To Acquire DICE
Mergers Are Down, but These 2 Sectors Are Booming
Short Volatility Alert: Dice Therapeutics
See More Headlines
Receive DICE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DICE Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:DICE
Fax
N/A
Employees
71
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$55.75
High Stock Price Target
$71.00
Low Stock Price Target
$48.00
Potential Upside/Downside
+17.2%
Consensus Rating
Hold
Rating Score (0-4)
2.30
Research Coverage
10 Analysts

Profitability

Net Income
$-83,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.13 million
Book Value
$10.86 per share

Miscellaneous

Free Float
45,392,000
Market Cap
$2.27 billion
Optionable
Not Optionable
Beta
1.03
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. J. Kevin Judice Ph.D. (Age 59)
    Founder, CEO & Director
    Comp: $840k
  • Mr. Scott Robertson
    Chief Bus. & Financial Officer
  • Dr. Timothy Lu M.D. (Age 48)
    Ph.D., Chief Medical Officer
    Comp: $700k
  • Dr. John R. Jacobsen Ph.D. (Age 54)
    Chief Scientific Officer
  • Ms. Mary Riley J.D.
    Gen. Counsel
  • Mr. Venkat Thalladi Ph.D.
    Sr. VP of CMC
  • Mr. Paul Fatheree
    Sr. VP of Medicinal Chemistry

DICE Stock Analysis - Frequently Asked Questions

Should I buy or sell DICE Therapeutics stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DICE Therapeutics in the last twelve months. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DICE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DICE, but not buy additional shares or sell existing shares.
View DICE analyst ratings
or view top-rated stocks.

What is DICE Therapeutics' stock price target for 2024?

10 brokers have issued 1-year target prices for DICE Therapeutics' stock. Their DICE share price targets range from $48.00 to $71.00. On average, they predict the company's share price to reach $55.75 in the next year. This suggests a possible upside of 17.2% from the stock's current price.
View analysts price targets for DICE
or view top-rated stocks among Wall Street analysts.

How were DICE Therapeutics' earnings last quarter?

DICE Therapeutics, Inc. (NASDAQ:DICE) announced its quarterly earnings results on Friday, November, 12th. The company reported ($2.30) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by $1.77.

When did DICE Therapeutics IPO?

DICE Therapeutics (DICE) raised $160 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 10,000,000 shares at $15.00-$17.00 per share.

This page (NASDAQ:DICE) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners